 NEW YORK--BUSINESS WIRE--- RCKT ASH2020--Rocket Pharmaceuticals, Inc. NASDAQ: RCKT Rocket, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces preliminary clinical data from its Phase 1 clinical trial of RP-L301 for the treatment of Pyruvate Kinase Deficiency PKD, showing significant improvement in hemoglobin levels and transfusion independence over the initial 3-months following therapy. These results were prese 